122 related articles for article (PubMed ID: 27859873)
1. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported.
Rosich Martí I; Allepuz A; Rodriguez Palomar G; Ortin Font F; Soler Cera M
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):91-96. PubMed ID: 27859873
[TBL] [Abstract][Full Text] [Related]
2. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
Puri R; Nissen SE; Menon V; Shao M; Hsu A; Bakris GL; Kastelein JJ; Williams B; Armbrecht J; Brunel P; Kataoka Y; Nicholls SJ
Atherosclerosis; 2015 Dec; 243(2):553-9. PubMed ID: 26523993
[TBL] [Abstract][Full Text] [Related]
3. Dual renin-angiotensin-aldosterone blockade: Implementation of published research and Dear Doctor letters in ambulatory care: A retrospective observational study using prescription data.
Angelow A; Ploner T; Grimmsmann T; Walker J; Chenot JF
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):530-537. PubMed ID: 32162407
[TBL] [Abstract][Full Text] [Related]
4. In brief: aliskiren trial terminated.
Med Lett Drugs Ther; 2012 Jan; 54(1382):5. PubMed ID: 22267213
[No Abstract] [Full Text] [Related]
5. Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors.
Mahmoudpour SH; Asselbergs FW; de Keyser CE; Souverein PC; Hofman A; Stricker BH; de Boer A; Maitland-van der Zee AH
Int J Clin Pharm; 2015 Dec; 37(6):1095-103. PubMed ID: 26159317
[TBL] [Abstract][Full Text] [Related]
6. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.
Chang J; Yang W; Kahler KH; Fellers T; Orloff J; Bensimon AG; Yu AP; Fan CP; Wu EQ
Am J Cardiovasc Drugs; 2011; 11(1):21-32. PubMed ID: 21142294
[TBL] [Abstract][Full Text] [Related]
7. Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports.
Dubrall D; Schmid M; Stingl JC; Sachs B
PLoS One; 2020; 15(3):e0230632. PubMed ID: 32214375
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the latest evidence relating to renin-angiotensin system inhibitors.
Escobar C; Barrios V
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):847-58. PubMed ID: 23560616
[TBL] [Abstract][Full Text] [Related]
9. Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry.
Kistner I; Zeymer U; Dechend R; Hagedorn I; Riemer T; Bramlage P; Pittrow D; Senges J; Schmieder RE
J Clin Hypertens (Greenwich); 2016 Oct; 18(10):1045-1053. PubMed ID: 27094460
[TBL] [Abstract][Full Text] [Related]
10. Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.
Schlienger RG; Korn JR; Wehler E; Lopez Leon S; Yeaw J
Am J Cardiovasc Drugs; 2017 Dec; 17(6):465-474. PubMed ID: 28779444
[TBL] [Abstract][Full Text] [Related]
11. The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry.
Friedrich S; Zeymer U; Dechend R; Hagedorn I; Riemer T; Zemmrich C; Bramlage P; Pittrow D; Senges J; Schmieder RE
J Hum Hypertens; 2015 May; 29(5):316-23. PubMed ID: 25273857
[TBL] [Abstract][Full Text] [Related]
12. Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.
Li SY; Chen YT; Yang WC; Tarng DC; Lin CC; Yang CY; Liu WS
BMC Nephrol; 2012 Aug; 13():89. PubMed ID: 22917002
[TBL] [Abstract][Full Text] [Related]
13. Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Gokhale M; Girman C; Chen Y; Pate V; Funk MJ; Stürmer T
Pharmacoepidemiol Drug Saf; 2016 May; 25(5):512-20. PubMed ID: 26860956
[TBL] [Abstract][Full Text] [Related]
14. A physician targeted intervention improves prescribing in chronic heart failure in general medical units.
Chua CC; Hutchinson A; Tacey M; Parikh S; Lim WK; Aboltins C
BMC Health Serv Res; 2018 Mar; 18(1):206. PubMed ID: 29566753
[TBL] [Abstract][Full Text] [Related]
15. ACE inhibitor and ARB medication use among Medicaid enrollees with diabetes.
Lora CM; Sokolovsky AW; Touchette DR; Jin J; Hu X; Gao W; Gerber BS
Ethn Dis; 2013; 23(2):189-95. PubMed ID: 23530300
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
[TBL] [Abstract][Full Text] [Related]
17. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
Gilbert CJ; Gomes T; Mamdani MM; Hellings C; Yao Z; Garg AX; Wald R; Harel Z; Juurlink DN
Can J Cardiol; 2013 May; 29(5):586-91. PubMed ID: 23541666
[TBL] [Abstract][Full Text] [Related]
18. Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.
Raptis AE; Bacharaki D; Mazioti M; Marathias KP; Markakis KP; Raptis SA; Dimitriadis GD; Vlahakos DV
Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):416-9. PubMed ID: 22441720
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
20. Direct renin inhibitor induced renal failure.
Vallakati A; Chandra PA; Hollander G; Shani J
Am J Ther; 2014; 21(2):e53-5. PubMed ID: 23665882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
